Diadem Biotherapeutics

Engineering the next class of biologics to treat chronic inflammatory diseases

Company Details

Diadem is engineering exosomes to be inhalable cell-specific immune modulators. Exosomes are small, virus-sized particles released by cells to communicate throughout the body. Diadem plans to develop a SARS-CoV-2 vaccine by engineering exosomes with surface bound SARS-CoV-2 proteins and immune-stimulating ligands, effectively turning them into non-replicative virus-like particles (VLP). To increase immune response and memory for the SARS-CoV-2 antigen, the VLPs can be engineered with immune stimulating ligands (e.g. 4-1BB).

Company People

Woytek Bartkowski

Woytek Bartkowski
CTO & Co-Founder

Mickey Pentecost

Mickey Pentecost
CEO & Co-Founder

Diadem Biotherapeutics News

VIEW ALL

You might also be interested in

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.